

A REVIEW OF AVAILABLE LITERATURE AND SCIENTIFIC STUDIES ON HERBS CONDUCTED SO FOR CONCERNING TREATMENT OF AMAVATA (W.S.T RHEUMATOID ARTHRITIS)

Kumar Anant¹, Kumar Surjeet^{2*}, Rani Khushboo, Sharma Amit Kumar⁴ and Tewari Aditaya Nath⁵

^{1,2,3}MD Scholar, PG Dept. of Rog Nidan Evum Vikriti Vigyan, Ch. Brahma Prakash Ayurveda Charak Sansthan, Khera Dabur Najafgarh, New Delhi-73.

⁴Associate Professor, Dept. of Rachna Sharir, Ayurveda and Unani Tibbia college New Delhi.

⁵Associate Professor, PG Dept. of Rog Nidan Evum Vikriti Vigyan, Ch. Brahma Prakash Ayurveda Charak Sansthan, Khera Dabur Najafgarh, New Delhi-73.

Article Received on
14 October 2017,

Revised on 05 Nov. 2017,
Accepted on 26 Nov. 2017

DOI: 10.20959/wjpr201716-10277

*Corresponding Author

Kumar Surjeet

MD Scholar, PG Dept. of
Rog Nidan Evum Vikriti
Vigyan, Ch. Brahma
Prakash Ayurveda Charak
Sansthan, Khera Dabur
Najafgarh, New Delhi-73.

ABSTRACT

The *Amavata* (Rheumatoid Arthritis) is the most common disease presently seen worldwide affecting approximately 1 to 2% of adult population. As per the Ayurveda provoked *Ama* and vitiated *Vata* simultaneously lodge in *Trika* and *Sandhi* and leads to *stabdhata* (stiffness), *shotha* (swelling) *shoola* (pain) in the body. The bodyache, loss of taste, heaviness, fever, and indigestion are also founded in *Amavata*. The *Amavata* has been challenging problems to the medical field. Various treatment protocols are applied in this disease with partial success. In the modern system of medicine the treatment of *Amavata* is immuno-modulators, Anti-inflammatory and Analgesic in which the steroid and non-steroid (NSAIDs) drugs are used which shows serious side effects like gastrointestinal ulceration and bleeding,

hepatotoxicity, stomatitis, dyslipidaemia. The prevalence of Rheumatoid Arthritis suggests that there is no complete integrated regimen to cure this disease or to pacify its symptoms. To provide a better life style to patient, some cost effective safer drugs with minimal or no side effect is highly require. The treatment in Ayurvedic literature is vast but yet little explored. Therefore there is need to explore and generate necessary evidence for Ayurvedic

management of this disease. The primary aim of this paper is to review the available literature along the experimental studies conducted to date.

KEYWORDS: *Amavata*, Rheumatoid Arthritis, Internet, Published Article.

INTRODUCTION

The *Amavata* is resultant combined effect of simultaneous aggravation of two pathological entities- *Ama* and *Vata*. The *Ama* is undigested harmful toxic metabolite of *Agnimandya* and *Vata dosha* vitiated by its etiological factor. When these two factors simultaneously take part in *Samprapti* (pathogenesis) than resultant disease become very difficult to treat. The *Samprapti* (pathogenesis) starts from the *Annavaha Srotasa* and then extend through *Madhyama rog marga* with special inclination for *Kapha Sthanas* especially *Sandhi* (joints). In such condition, patient weeps in agony of pain and reduced functional capacity with severe stiffness and crippling deformity of joint, which make them bed ridden.^[1]

DEFINITION

The condition in which provoked *Ama* and *Vata* simultaneously lodge in *trika* (pelvic, shoulder, girdle) and *sandhi* leading to *stabdhata* (stiffness) this condition has been identified as *Amavata*.^[2] Rheumatoid arthritis described in the modern system of medicine can be correlated with *Amavata*. Rheumatoid arthritis is a chronic inflammatory disease of unknown etiology marked by a symmetric, peripheral polyarthritis. It is most common form of chronic inflammatory arthritis and often results in joint damages and physical disability.^[3] The disease prevalence worldwide is approximately 0.8% (0.3% to 2.1%) of the adult population. Like many other autoimmune disease RA occurs more commonly in female than male with a 3:1 ratio. In India, the prevalence of RA is 0.5% to 0.7%. The peak age of onset in the fourth and fifth decade of the life with more than 75% patients developing disease between 30 and 50 years of age.^[4]

The Basic principles of Modern-day Treatment of Rheumatoid Arthritis are the tight disease control strategy' based on objectified assessment of disease activity as a guide for response-driven targeted treatment for improved outcome.

The goals of RA management are to control pain and swelling, delay disease progression, minimize disability and improve quality of life. Non-steroidal Anti-inflammatory drugs (NSAIDs) have both analgesic and anti-inflammatory property but do not change disease

outcome and side effects are gastrointestinal ulcer (15-20% of patients) ulcer with bleeding and perforation (2-4% of patient).^[5] Glucocorticoid have greater action on joint pain but have numerous side effect including adrenal suppression, ulcer and osteoporosis.^[6] DMARDs, such as the currently popular methotrexate, sulfasalazine, leflunomide reduced the progression of joint erosion but have slow onset and no analgesic activity. DMARDs can produce severe systemic toxicity, however, including infections (being immunosuppressive). Methotrexate has been shown to cause pulmonary complication.^[7]

Ayurveda is widely practiced system of traditional medicine India. In Ayurveda following treatment protocols are prescribed by various *Acharyas*. *Acharya Cakradutta* was first to describe the line of treatment and drugs for *Amavata*. Further *Bhavapraksha* and *Yogratnakar* followed the same protocols as *Langhana*, *Swedana*, *Dipana*, *Virechana*, *Snehapana*, *Basti*, *Kshar Basti* supported by most of the *Acharya* for the treatment of *Amavata*.^[8,9,10]

METHODS AND MATERIALS

Following the line of treatment described by ancient *Acharyas* of Ayurveda, many studies has been conducted and some has been published showing significant improvement in the symptoms of *Amavata*. Details of those articles available at internet has been collected and analysed.

The details has been summarised as under -

| Sr. | Drug | Effective Dose | Study Models | Duration | Sample size | Result |
|-----|---|---------------------------------|----------------|------------------|-------------|--|
| 1 | <i>Shiva guggulu & Simhanada guggul</i> ^{*[14]} | 6gm/day | Clinical trial | 8 week | 70 | Highly significant P<0.001 T=3.45 |
| 2 | <i>Vardhamana pippli Rasayana</i> ^{*[15]} | 1gm BD increasing up to 5 gm BD | Clinical trial | 15 days | 73 | Highly significant P<0.001 T=6.73 |
| 3 | <i>Aswagandha powder & siddha makardhwaj</i> ^{*[16]} | 5gm & 100mg BD | Pilot study | 3 week 4 week | 75 | Highly significant P<0.01 DAS=5.01+/-0.36 to 4.29+/-0.21 |
| 4 | <i>Amavatari Ras</i> ^{*[17]} | 750mg BD | Clinical trial | 30 days | 20 | Highly significant P<0.001 T=2.04-4.06 |
| 5 | <i>Amrita ghruta</i> ^{*[18]} | 15gm BD | Clinical trial | 45 days | 28 | Highly significant P<0.001 T=5.09-9.70 |
| 6 | <i>Ajmodadi churna & Eranda tail</i> ^{*[19]} | 5gm BD 10 ml BD | Clinical trial | 30 days | 20 | Highly significant P<0.001 |

| | | | | | | |
|----|---|----------------------|----------------|-------------------------------|----|---|
| | | | | | | $X^2=42.61$ |
| 7 | <i>Rasona pinda</i> ^{*[20]} | 50-60mg/kg | Clinical trial | 90 days | 50 | Significant $P>0.05$ $t=0.89-1.02$ |
| 8 | <i>Vatari guggul & Matra Basti</i> ^{*[21]} | 500mg TDS & 60ml/day | Clinical trial | 45 days 21 days | 50 | Highly significant $P=0.001$ $t= 5.61-16.36$ |
| 9 | <i>Kshara Basti & Nirgundi Ghana Vati</i> ^{*[22]} | Vati-500mg TDS | Clinical trial | 16days 30 days | 50 | Highly significant $P<0.001$, $t=3.87$ & $p>0.001$, $t=16.17$ |
| 10 | <i>Panchamooladi kaala Basti</i> ^{*[23]} | 80ml/day | Clinical trial | 21days | 12 | Highly significant $P<0.001$ $T=8.83-10.53$ |
| 11 | <i>Shunthi Churna</i> ^{*[24]} | 2gm BD | Clinical trial | 30 days | 30 | Highly significant $P<0.01$ |
| 12 | <i>Bhallattaka Kshira paka</i> ^{*[25]} | 80ml BD | Clinical trial | 1 week alternate to 4 week | 21 | Highly significant $P<0.01$ $T=2.40-3.7$ |
| 13 | <i>Rasna Rasonadi Ghana Vati</i> ^{*[26]} | 250mg TDS | Clinical trial | 90 days | 51 | Highly significant $P<0.001$ $T=15.67-17.34$ |
| 14 | <i>Haritaki & Trivrutadi churna</i> ^{*[27]} | 5gm BD both | Clinical trial | 30 days | 35 | Highly significant $P<0.02$, $t=3.07-5.68$ & $P<0.01-0.05$, $t=4.15$ |
| 15 | <i>Alambushadi churna</i> ^{*[28]} | 6gm BD | Clinical trial | 6 week | 30 | Highly significant $P=0.001$ $SE=0.001-0.007$ |
| 16 | <i>Sunti churna & Vrudhadaru mool churna</i> ^{*[29]} | 500mg TDS | Clinical trial | 21 days | 15 | Both drugs show significant result. |

Besides these traditional formulations some standardised formulation has been also clinically tested and they have also shown significant improvement in symptoms with good safety profile. Detailed of these formulations are as under.

RA-1: A standardized formulation, called RA-1, was prepared from purified plant extracts of *Withania somnifera*, *Boswellia serrate*, *Zingiber officinale* and *Curcuma longa*, and evaluate over 16 weeks in a randomized double blind, placebo controlled, parallel efficacy, single centre phase II drug trial. Here 182 patients with active on chronic RA were enrolled and efficacy assessed as per protocol. Significant with $p<0.05$, in conclusion RA-1 was found to be a moderate DMARD with an excellent safety profile.^[30,31]

IRA-01: IRA-01 contain extracts of *Boswellia serrate*, *Trigonella foenum*, *Linum usitatissimum*, *Curcuma longa*, *Camellia sinensis*, *Tribulus terrestris* and *Piper longum*. Here

130 RA active patients enrolled in the study with one year follow up. On completion significant improvement in all efficacy variables including joint pain, swelling and stiffness. HAQ was found (some $p < 0.001$). It was concluded that IRA-01 was a slow onset DMARD with modest efficacy, excellent safety profile.^[32]

NMITLI/B1: This Ayurvedic formulation developed by NMITLI. Project contains extracts of *Tinospora cardifolia*, *Withania somnifera*, *Tribulus terrestris*, *Zingiber officinale*. This trial compared B1 with proprietary of monoherb preparation (a formulation of *Semicarpus anacardium*) and hydroxychloroquin (HCQS). Total 121 patients with active RA were randomized in three arms, single blind parallel efficacy, 24 week. The ACR-20 improvement response was demonstrated 44%, 55% and 36% of the B-1, HCQS and mono-herb respectively. Result suggests the B-1 drug similar efficacy to HCQS, but with greater safety profile.^[33]

ORTHOKAP TAB: The study was done on 20 patient with 2 tab twice daily (each tab=500mg). the trial drug Orthokap herbomineral combination of *Rasabhra guggul*, *Vata Gajedra Singha*, *Shallaki satwa*, *Shankh Bhasma*. The clinical study shown significant effects in improving condition of *Amavata*.^[34]

DISCUSSION

The *Ama* and vitiated *Vata* is described in Ayurvedic literature is root cause of stiffness, pain and swelling. So the drug which shows *Amapachana*, *Amashodhak* and *Vata* balancing pharmacodynamics property is highly effective in this disease (Like *Shunthi churna*, *Alambushadi churna*, *Ajmodadi churna*, *Rasona pinda* etc.). These drugs increase *Agni* and checked formation of *Ama*, resulting anti-inflammatory and analgesic mode of action.

Gold containing drugs comprise a class of distinctive Anti-arthritis agents (DMARDs) used when NSAIDs are insufficient to treat severe case of Rheumatoid arthritis. The reported remission of RA with gold therapy is 30 per cent.^[35] It is fascinating that 'gold' in its Ayurvedic ash form (like *Sidh Makardhwaj*) has been used to treat rheumatoid arthritis since ancient times. Similarly the *Rasayana* (like *Vardhamana pippali*, *Aswagandha* etc.) aims to increase body's resistance to disease, delay aging and promote body strength and intellect. *Ricinus communis* (*Erand*) and *commiphora mukul* (*guggul*) are prime example of potent anti-arthritis medicinal plant described in *Charak samhita*.

The *Panchakarma* comprises treatment curative to *dosha* imbalance, is indicated to specific stage of the disease. They are widely used to treat many form of arthritic condition, including RA. *Langhana* in initial stage helps for strengthened digestive and metabolic system. The Oleation therapy (*Basti*, massage) aim to cleanse and purify the body to restore *tridosha* equilibrium reliving pain by local application.^[36] In the *Amavata* dry sudation (*Ruksha sweda*) is advocated. *Basti* is the treatment of choice for *vata* ailments. In *Amavata vaitarana basti* is popular treatment widely practised and studied as well. The *virechana karma* is described for effective management of *Amavata*; it might be responsible for *Agnivardhana* and evacuation of *Ama*, which is the main culprit of this disease.^[37]

CONCLUSION

Considering all the literature and data available regarding the treatment of *Amavata*, it can be said that the management of *Amavata* in Ayurveda is almost similar to the conventional allopathic therapy, because both primarily aim to reduced pain, swelling and stiffness of the joints. However herbal therapy appears to be safe as compared modern system of medicine as Ayurvedic preparations include mainly herbs that make the body work more efficiently. The allopathic drugs containing chemicals interfere in the body's natural process, resulting in unwanted side effects. Because they offer fewer or no side effects, herbal therapy should be preferred in the treatment of *Amavata* (RA).

REFFRANCES

1. Rajesh Boria, Niyan joshi, Dilip pandey, Clinical efficacy of Panchamuladi kaala basti in management of Amavata (RA), Ayu, Jan-March, 2011; 32(1): 90-94.
2. Upadhyay Yadunandana, Madhava Nidanam, Amavata Nidanam, edition reprint-2016, Chaukhambha publication, 509.
3. Harrison`s Principle of Internal medicine, 17th edition, Mc-Graw-Hill Companies. Ankoee Shah, E. William St. Clair, 380: 2136.
4. A.N Malaviya, Y.P. Monjal, API Textbook of Medicine Vol.-II, 9th edition 2012 JP brothers medical publisher`s (p) Ltd, 1829.
5. Gajendra Kumar, Amitasrivastava, Surender kumar at al. Effecacy and Safty evaluation of Ayurvedic treatment (Aswagandha powder & Sidha makardhwaj) in Rheumatoid Arthritis protection. XX1.

6. Gotzsche PC, Johansen HK, short term low dose corticosteroid Vs placebo & non-steroidal Anti-inflammatory drug in Rheumatoid Arthritis, Cochrane database sys Rev., 2002; 2: CD000189.
7. Dawson JK, Graham DR, Desmonds, Fewins HE, Lynch MP, Investigation of chronic pulmonary effect of low dose oral methotrexate in patients of Rheumatoid Arthritis- A prospective study incorporating HRCT scanning and pulmonary function test, Rheumatology (oxford), 2002; 41: 262-267. (((xx3))).
8. Sri Jagadishhvara Prasad, Tripathi, edition reprint, Chakradutta, Chaukhambha Publication, 2008; 225.
9. Asha kumara, PV Tewari, Yogaratnakara, Chaukhambha Publication, 2010; 225.
10. Dr Kanjiv Lochan, Bhaisajya Ratnavali, edition reprint, Chaukhambha Publication, 2009; II: 284.
11. Sri Jagadishhvara Prasad Tripathi, Chakradatta, Amavata chikitsa Ch.-25, Chaukhambha Sanskrit Publication, edition reprint, 2008; 225; 123.
12. Asha kumara, PV tewari, Yogaratnakara, Amavatadhikara, Ch.-28, Chaukhambha Sanskrit Publication, edition, 2010; II: 641-642.
13. Dr. Kanjiv Lochan, Bhaisajya Ratnavali, Amavata Chikitsa prakaran, Ch.-29, Chaukhambha Sanskrit Publication edition reprint, 2009; II: 284.
14. Shewata A Pandey, Nayan P Joshi, Dilip M. Pandey, Clinical efficacy of Shiva guggulu and Simhanada guggulu in Amavata (RA), Ayu, Apr-Jun, 2012; 33(2): 247-254.
15. Anamika Soni, Kalapi Patel, S.N Gupta, Clinical evaluation of Vardhamana pippli rasayan in management of Amavata (RA). Ayu, Apr-Jun, 2011, 32(2): 177-180.
16. Gajendra kumar, Amit Srivastva, Yogendra kumar gupta, efficacy and safety evaluation of Ayurvedic treatment Aswagandha powder and Siddha Makardhwaj in Rheumatoid Arthritis: A pilot prospective study Indian J Med. Res., Jan, 2015; 141(1): 100-106.
17. Vijayendra G Bhat, Niveditha hebbbar YR, Shrilatha Kamath, Management of Amavata with Amavatari Ras individually along with Valuka sweda, Ayurpharm Int J Ayur Alli Sai., 2016; 5(12): 157-167.
18. P.S Leukurwale, Kamlesh Pandey and P. Yadaiah, Management of Amavata with Amrita Ghrita, A clinical study Ayu., Oct-Dec, 2010; Oct-Dec 31(4): 430-435.
19. Mishra PK, Rai NP Effect of Castor oil with Ajmodadi churna & Ruksha Sweda in the Management of Rheumatoid Arthritis vis-à-vis Amavata, IJPR, 2014; 3: 1-1/00150.
20. Jai Prakash singh, Mera Antiwal, S.K Tiwari, Clinical efficacy of Rasona pinda in the management of Amavata (Rheumatoid Arthritis); Ayu, July-Sep, 2010; 31(3): 280-286.

21. Rita Khagram, Charmi S. Mehta et al Clinical effect of Matra Basti and Vatari guggula in management of Amavata (Rheumatoid Arthritis); Ayu, July- Sep, 2010; 31(3): 343-350.
22. Krishna Thanki, Nilesh Bhatt, V.D Shukla, Effect of Kshara Basti and Nirgundi Ghana Vati on Amavata(Rheumatoid Arthritis). Ayu, Jan-Mar, 2012; 33(1): 50-53.
23. Rajneesh Baria, Nayan Joshi, Dilip Pandya, Clinical efficacy of Panchmuladi kaala basti in management of Amavata (Rheumatoid Arthritis). Ayu, Jan-Mar; 2011; 32(1): 90-94.
24. Milan Jayantibhai prajapati, A pharmaco-clinical study of Shunthi Churna in management of Amavata (Rheumatoid Arthritis); IJDR, June-2017; 7(06): 13029-13031.
25. Vinod N. Ade, Role of Bhallataka Kshira paka in the management of Amavata (Rheumatoid Arthritis), A clinical study JID, 150260A, 2015; 3(3): 122-128.
26. Raja Ram Mahto, Alankruta R. Dave & V.D Shukla, A comparative study of Rasona Rasnadi Ghan Vati and Simhanada guggulu on Amavata (Rheumatoid Arthritis), Ayu., Jan-Mar; 2011; 32(1): 46-54.
27. Sandip D. Bansode, Deepak A Deshpande. A comparative study of Haritaki Prayog and Trivrutadi churna in management of Amavata (Rheumatoid Arthritis) Ayurpharm Int J Ayur, 2016; 5(6): 83-89.
28. Dr. Santosh Kamble, Dr. Prakash Mane et al. A Clinical evaluation of Alambushadi Churna(YR) in Amavata; IJCR, June-2015; 7(6): 17525-17529.
29. Devulapully Anuradha, effect of Sunthi Churna and Vrudhadaru moola churna in Amavata management; JPSI, Sep-Oct 2012; 1(5): 71-72.
30. Begum VH, Sadique J. Long term effect of herbal drug Withania Somnifera on adjuvant induced arthritis in rats Indian J Exp Biol., 1988; 26: 877-82.^[RA-1]
31. Arvind Chopra, Manjit Saluju, Grish Tillu; Ayurveda-Modern medicine interface: A critical appraisal of studies of Ayurvedic medicine to treat osteoarthritis and Rheumatoid Arthritis; J Ayurveda integer med., July-Sep, 2010; 1(3): 190-198.^[RA-1]
32. Ghosal S, Lal J, Shrivastava R, Bhattacharya SK, Upadhyay SN, Jaiswal Ak, et al. immunomodulatory and CNS effects of sitoinosides IX and X, two new glycowithanolides from W somnifera. Phytother res., 1989; 201.^{IRA-01}
33. Ziauddin M, Phansalkar N, Patki P, Diwanay S, Patwardhan B. Studies on the immunomodulatory effects of Aswagandha. J Ethnopharmacol, 1996; 50: 69-76. [PubMed].
34. Dr. Dilip kumar Pati. A clinical trial of Orthokap tablet; Ayurlog NJRAS, issue-I Jan-March 2015.

35. Lehman AJ, Esdaile JM, Klinkhoff AV, et al randomised double blind, double observer, placebo-controlled multicentre trial of combination of methotrexate and intramuscular gold therapy in RA. METGO study. *Arthritis Rheum*, 2005; 52: 1360-70.
36. Arvind chopra, Manjit saluja and Girish tillu, Ayurveda-modern medicine interface: A critical appraisal of studies of Ayurvedic medicine to treat osteoarthritis and rheumatoid arthritis. *J Ayurveda Integr Med.*, Jul-Sep, 2010; 1(3): 190-198.
37. Sanjay kumar Gupta, Anup B Thakur, TS Dudhamal management of Amavata(RA) with diet and Virechanakarma, *Ayu*, 2015; 36(4): 413-415.